40 studies found for:    PDX1
Show Display Options
Rank Status Study
1 Withdrawn Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn®
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Folotyn;   Drug: Fusilev
2 Withdrawn Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn
Condition: Non Hodgkin's Lymphoma
Interventions: Drug: Fusilev;   Drug: Folotyn
3 Completed
Has Results
Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Pralatrexate Injection;   Drug: Erlotinib;   Dietary Supplement: Vitamin B12;   Dietary Supplement: Folic Acid
4 Completed
Has Results
Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies
Conditions: Relapsed or Refractory Lymphoproliferative Malignancies;   Hodgkin's Lymphoma;   Peripheral T-cell Lymphoma;   B-cell Lymphoma;   Waldenstrom's Macroglobulinemia
Interventions: Drug: Pralatrexate Injection;   Drug: Gemcitabine Hydrochloride;   Dietary Supplement: Vitamin B12;   Dietary Supplement: Folic Acid
5 Completed Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Condition: Cutaneous T-cell Lymphoma
Interventions: Drug: Pralatrexate Injection;   Dietary Supplement: Vitamin B12;   Dietary Supplement: Folic Acid
6 Active, not recruiting Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Conditions: Cutaneous T-cell Lymphoma;   Mycosis Fungoides;   Sezary Syndrome;   Primary Cutaneous Anaplastic Large Cell Lymphoma
Interventions: Drug: Pralatrexate Injection;   Drug: Bexarotene Capsules;   Dietary Supplement: Vitamin B12;   Dietary Supplement: Folic Acid
7 Active, not recruiting Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer
Conditions: Adenocarcinoma of the Esophagus;   Adenocarcinoma of the Gastroesophageal Junction;   Diffuse Adenocarcinoma of the Stomach;   Intestinal Adenocarcinoma of the Stomach;   Mixed Adenocarcinoma of the Stomach;   Recurrent Esophageal Cancer;   Recurrent Gastric Cancer;   Squamous Cell Carcinoma of the Esophagus;   Stage III Esophageal Cancer;   Stage III Gastric Cancer;   Stage IV Esophageal Cancer;   Stage IV Gastric Cancer
Interventions: Drug: pralatrexate;   Drug: oxaliplatin;   Other: pharmacogenomic studies;   Genetic: RNA analysis;   Genetic: polymorphism analysis;   Genetic: polymerase chain reaction;   Genetic: microarray analysis;   Procedure: esophagogastroduodenoscopy;   Procedure: biopsy;   Other: laboratory biomarker analysis
8 Terminated PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma
Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Mycosis Fungoides/Sezary Syndrome;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Mycosis Fungoides/Sezary Syndrome;   Stage IV Small Lymphocytic Lymphoma;   Unspecified Adult Solid Tumor, Protocol Specific;   Waldenström Macroglobulinemia
Interventions: Drug: tanespimycin;   Drug: belinostat;   Other: laboratory biomarker analysis;   Other: pharmacological study
9 Recruiting Validation of Functional Imaging as Predictive Tool for Outcome of Mandibular Replacement Appliance Therapy in Obstructive Sleep Apnea Hypopnea Syndrome Patients
Condition: Obstructive Sleep Apnea Syndrome
Interventions: Radiation: CT scan;   Device: Alice PDx polygraphy
10 Recruiting Erlotinib in Combination With Pralatrexate in Advanced Malignancies
Conditions: Advanced Cancers;   Solid Tumors
Interventions: Drug: Erlotinib;   Drug: Pralatrexate
11 Completed Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
Condition: Head and Neck Cancer
Intervention: Drug: Pralatrexate With Vitamin B12 and Folic Acid
12 Recruiting Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Condition: Peripheral T-cell Lymphoma
Interventions: Drug: Pralatrexate injection;   Dietary Supplement: Vitamin B12;   Dietary Supplement: Folic Acid
13 Recruiting Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
Conditions: Lymphoid Malignancies;   Multiple Myeloma;   Lymphoma;   Hodgkin Lymphoma;   Non-hodgkin Lymphoma
Interventions: Drug: Pralatrexate;   Drug: Romidepsin
14 Recruiting KW 0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
Condition: Adult T-cell Leukemia-Lymphoma
Interventions: Biological: KW-0761;   Drug: investigator's choice (pralatrexate; gemcitabine/oxaliplatin; dexamethasone/cisplatin/cytarabine))
15 Recruiting Phase II of Carbo/Pralatrexate in Rec. Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
Interventions: Drug: carboplatin;   Drug: pralatrexate
16 Recruiting Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Conditions: Relapsed Peripheral T-Cell Lymphoma;   Refractory Peripheral T-Cell Lymphoma
Interventions: Drug: Alisertib;   Drug: Pralatrexate;   Drug: Gemcitabine;   Drug: Romidepsin
17 Unknown  Pralatrexate and Fluorouracil in Treating Patients With Recurrent Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: pralatrexate;   Drug: fluorouracil;   Other: laboratory biomarker analysis;   Genetic: DNA analysis;   Other: high performance liquid chromatography;   Genetic: polymerase chain reaction;   Genetic: nucleic acid sequencing;   Other: pharmacological study;   Other: pharmacogenomic studies;   Genetic: polymorphism analysis
18 Active, not recruiting Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM
Condition: Multiple Myeloma
Interventions: Drug: velcade;   Drug: Pralatrexate
19 Active, not recruiting Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy
Conditions: Adenocarcinoma of the Esophagus;   Adenocarcinomas of the Gastroesophageal Junction;   Recurrent Esophageal Cancer;   Squamous Cell Carcinoma of the Esophagus;   Stage IV Esophageal Cancer
Interventions: Drug: pralatrexate;   Drug: docetaxel;   Radiation: fludeoxyglucose F 18;   Procedure: positron emission tomography
20 Recruiting Phase 2, Single Arm, Open Label Study of Folotyn in Combination With Oral Leucovorin to Prevent or Reduce Mucositis in Patients With PTCL
Conditions: Relapsed Peripheral T-Cell Lymphoma;   Refractory Peripheral T-Cell Lymphoma
Interventions: Drug: Folotyn and Leucovorin;   Drug: Folic Acid;   Drug: Vitamin B12

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years